Bristol Myers' bowel disease drug fails to meet main goal in late-stage study

Bristol Myers Squibb (BMY.N) said on Thursday its experimental drug to treat Crohn's disease, a chronic inflammatory bowel condition, failed to meet the main goal in a late-stage study.
Crohn's disease, which results in the swelling or inflammation of the intestines, affects over one million people in the U.S., according to government data.